000860707 001__ 860707
000860707 005__ 20210130000604.0
000860707 0247_ $$2doi$$a10.1002/mds.27626
000860707 0247_ $$2ISSN$$a0885-3185
000860707 0247_ $$2ISSN$$a1531-8257
000860707 0247_ $$2pmid$$apmid:30719763
000860707 0247_ $$2WOS$$aWOS:000461871300009
000860707 0247_ $$2altmetric$$aaltmetric:55027289
000860707 037__ $$aFZJ-2019-01372
000860707 082__ $$a610
000860707 1001_ $$00000-0001-8849-4233$$aDafsari, Haidar S.$$b0$$eCorresponding author
000860707 245__ $$aEuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease
000860707 260__ $$aNew York, NY$$bWiley$$c2019
000860707 3367_ $$2DRIVER$$aarticle
000860707 3367_ $$2DataCite$$aOutput Types/Journal article
000860707 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1553092228_28400
000860707 3367_ $$2BibTeX$$aARTICLE
000860707 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000860707 3367_ $$00$$2EndNote$$aJournal Article
000860707 520__ $$aObjectiveReal‐life observational report of clinical efficacy of bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson's disease (PD).MethodsIn this prospective, multicenter, international, real‐life cohort observation study of 173 PD patients undergoing STN‐DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed‐up using PDQuestionnaire‐8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)‐III, UPDRS‐IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention. Outcome changes were analyzed with Wilcoxon signed‐rank or paired t test when parametric tests were applicable. Multiple comparisons were corrected (multiple treatments/scales). Effect strengths were quantified with relative changes, effect size, and number needed to treat. Analyses were computed before and after propensity score matching, balancing demographic and clinical characteristics.ResultsIn all groups, PDQuestionnaire‐8, UPDRS‐IV, and NMSS total scores improved significantly at follow‐up. Levodopa equivalent daily dose was significantly reduced after STN‐DBS. Explorative NMSS domain analyses resulted in distinct profiles: STN‐DBS improved urinary/sexual functions, mood/cognition, sleep/fatigue, and the miscellaneous domain. IJLI improved the 3 latter domains and gastrointestinal symptoms. APO improved mood/cognition, perceptual problems/hallucinations, attention/memory, and the miscellaneous domain. Overall, STN‐DBS and IJLI seemed favorable for NMSS total score, and APO favorable for neuropsychological/neuropsychiatric NMS and PDQuestionnaire‐8 outcome.ConclusionsThis is the first comparison of quality of life, nonmotor. and motor outcomes in PD patients undergoing STN‐DBS, IJLI, and APO in a real‐life cohort. Distinct effect profiles were identified for each treatment option. Our results highlight the importance of holistic nonmotor and motor symptoms assessments to personalize treatment choices. © 2019 International Parkinson and Movement Disorder Society
000860707 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000860707 588__ $$aDataset connected to CrossRef
000860707 7001_ $$0P:(DE-HGF)0$$aMartinez‐Martin, Pablo$$b1
000860707 7001_ $$0P:(DE-HGF)0$$aRizos, Alexandra$$b2
000860707 7001_ $$0P:(DE-HGF)0$$aTrost, Maja$$b3
000860707 7001_ $$0P:(DE-HGF)0$$aSantos Ghilardi, Maria Gabriela$$b4
000860707 7001_ $$0P:(DE-HGF)0$$aReddy, Prashanth$$b5
000860707 7001_ $$0P:(DE-HGF)0$$aSauerbier, Anna$$b6
000860707 7001_ $$0P:(DE-HGF)0$$aPetry‐Schmelzer, Jan Niklas$$b7
000860707 7001_ $$0P:(DE-HGF)0$$aKramberger, Milica$$b8
000860707 7001_ $$0P:(DE-HGF)0$$aBorgemeester, Robbert W. K.$$b9
000860707 7001_ $$0P:(DE-HGF)0$$aBarbe, Michael T.$$b10
000860707 7001_ $$0P:(DE-HGF)0$$aAshkan, Keyoumars$$b11
000860707 7001_ $$0P:(DE-HGF)0$$aSilverdale, Monty$$b12
000860707 7001_ $$0P:(DE-HGF)0$$aEvans, Julian$$b13
000860707 7001_ $$0P:(DE-HGF)0$$aOdin, Per$$b14
000860707 7001_ $$0P:(DE-HGF)0$$aFonoff, Erich Talamoni$$b15
000860707 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b16$$ufzj
000860707 7001_ $$0P:(DE-HGF)0$$aHenriksen, Tove$$b17
000860707 7001_ $$0P:(DE-HGF)0$$aEbersbach, Georg$$b18
000860707 7001_ $$0P:(DE-HGF)0$$aPirtošek, Zvezdan$$b19
000860707 7001_ $$0P:(DE-HGF)0$$aVisser‐Vandewalle, Veerle$$b20
000860707 7001_ $$00000-0003-1040-2807$$aAntonini, Angelo$$b21
000860707 7001_ $$0P:(DE-HGF)0$$aTimmermann, Lars$$b22
000860707 7001_ $$00000-0003-2815-0505$$aRay Chaudhuri, K.$$b23$$eCorresponding author
000860707 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.27626$$gp. mds.27626$$n3$$p353-365$$tMovement disorders$$v34$$x1531-8257$$y2019
000860707 8564_ $$uhttps://juser.fz-juelich.de/record/860707/files/Dafsari_et_al-2019-Movement_Disorders.pdf$$yRestricted
000860707 8564_ $$uhttps://juser.fz-juelich.de/record/860707/files/Dafsari_et_al-2019-Movement_Disorders.pdf?subformat=pdfa$$xpdfa$$yRestricted
000860707 909CO $$ooai:juser.fz-juelich.de:860707$$pVDB
000860707 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b16$$kFZJ
000860707 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000860707 9141_ $$y2019
000860707 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000860707 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2017
000860707 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000860707 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000860707 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000860707 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000860707 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000860707 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000860707 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000860707 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000860707 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000860707 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2017
000860707 920__ $$lyes
000860707 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000860707 980__ $$ajournal
000860707 980__ $$aVDB
000860707 980__ $$aI:(DE-Juel1)INM-3-20090406
000860707 980__ $$aUNRESTRICTED